Skip to main content

Table 2 Associations of polymorphisms in A) TOP3A and B) BLM and cancer risk (presented as odds ratios and 95% confidence interval) in different cancer forms.a

From: Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study

Cancer type

Polymorphism

Risk allele %

Cases/controls

Genotype

Cases

Controls

OR

95% CI

AML/MDS

TOP3A

rs1563634 b

75/66

AA

11

14

1.0c, d

-

   

AG

54

52

1.3

0.53–3.1

   

GG

84

52

2.0

0.82–4.7

Malignant

melanoma

 

75/66

AA

12

14

1.0

-

   

AG

60

52

1.4

0.58–3.2

   

GG

96

52

2.2

0.93–5.1

Bladder

 

68/67

AA

3

19

1.0

-

cancer

  

AG

32

54

3.9

1.1–14

   

GG

25

66

2.5

0.67–9.1

Breast cancer

 

68/68

AA

19

16

1.0

-

   

AG

88

48

1.5

0.72–3.2

   

GG

92

66

1.2

0.57–2.5

AML/MDS

TOP3A

rs12945597

37/25

GG

61

64

1.0

-

   

GA

63

49

1.3

0.76–2.2

   

AA

22

5

4.9

1.7–14

Malignant

melanoma

 

32/25

GG

78

64

1.0

-

   

GA

72

49

1.2

0.74–2.0

   

AA

18

5

3.0

1.0–8.4

Bladder

 

36/30

GG

26

73

1.0

-

cancer

  

GA

25

49

1.4

0.75–2.8

   

AA

9

17

1.5

0.58–3.7

Breast cancer

 

31/26

GG

96

76

1.0

-

   

GA

84

40

1.7

1.0–2.7

   

AA

20

15

1.1

0.52–2.3

AML/MDS

BLM

rs401549

31/30

AA

65

57

1.0

-

   

AG

75

51

1.3

0.77–2.1

   

GG

9

10

0.77

0.29–2.0

Malignant

melanoma

 

36/30

AA

62

57

1.0

-

   

AG

90

51

1.6

0.98–2.7

   

GG

16

10

1.5

0.61–3.5

Bladder

 

37/30

AA

26

64

1.0

-

cancer

  

AG

24

67

0.90

0.47–1.7

   

GG

10

8

3.1

1.1–8.7

Breast cancer

 

34/33

AA

87

58

1.0

-

   

AG

94

61

1.0

0.65–1.6

   

GG

19

12

1.1

0.48–2.4

AML/MDS

BLM

rs2532105

16/12

CC

103

90

1.0

-

   

CT+TTe

46

27

1.4

0.83–2.5

Malignant

melanoma

 

18/12

CC

109

90

1.0

-

   

CT+TT

59

27

1.8

1.1–3.2

Bladder cancer

 

20/10

CC

40

111

1.0

-

   

CT+TT

20

28

2.1

1.0–4.2

Breast cancer

 

17/13

CC

133

104

1.0

-

   

CT+TT

67

27

2.0

1.2–3.3

  1. a Observe that the control group for AML/MDS (acute myeloid leukemia/myelodsyplastic syndromes) and malignant melanoma case groups was the same. Logistic regression, adjusted for age and sex. Statistically significant associations (p ≤ 0.05) are denoted in bold.
  2. bAccession number for polymorphisms in the SNP database of National Centre of Biotechnology Information, http://0-www-ncbi-nlm-nih-gov.brum.beds.ac.uk/sites/entrez?db=snp
  3. c Reference category.
  4. d For rs1563634, the reference category was changed to the variant allele in order to display cancer risk increment, and the risk allele frequency denotes thus the more common allele.
  5. e Due to low variant allelic frequencies, the variant genotypes were merged.